These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 18924461)

  • 21. [Economic evaluation of health technologies: theory and practice].
    Abadi-Korek I; Shemer J
    Harefuah; 2008 Jun; 147(6):509-11, 574. PubMed ID: 18693627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Use of pharmacoeconomics analyses to health protection].
    Drozd M
    Wiad Lek; 2002; 55 Suppl 1():76-9. PubMed ID: 15002222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What is next for pharmacoeconomics and outcomes research in Asia?
    Doherty J; Kamae I; Lee KK; Li H; Li SC; Liu GG; Tarn YH; Yang BM
    Value Health; 2004; 7(2):118-32. PubMed ID: 15164802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic evaluation of sublingual immunotherapy: an analysis of literature.
    Ciprandi G; Agostinis F; Amoroso S; Ariano R; Barbato A; Bassi M; Cadario G; Campi P; Cardinale F; Romano C; Incorvaia C; Danneo R; Dal Bo S; Di Gioacchino M; Fiocchi A; Galimberti M; Galli E; Giovannini M; La Grutta S; Lombardi C; Marcucci F; Marseglia GL; Mastrandrea F; Minelli M; Nettis E; Novembre E; Ortolani C; Pajno G; Piras PP; Passalacqua G; Patriarca G; Pucci S; Quercia O; Romano A; Schiavino D; Sforza M; Tosca MA; Tripodi S; Zambito M; Puccinelli P; Frati F
    Eur Ann Allergy Clin Immunol; 2007; 39 Spec No():21-6. PubMed ID: 18924463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficiency versus quality in the NHS, in Portugal: methodologies for evaluation].
    Giraldes Mdo R
    Acta Med Port; 2008; 21(5):397-410. PubMed ID: 19187682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacoeconomic impact of compliance].
    Agh T; Mészáros A
    Acta Pharm Hung; 2010; 80(2):75-80. PubMed ID: 20684381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health economic issues in the treatment of drug-resistant serious Gram-positive infections.
    Nathwani D
    J Infect; 2009 Sep; 59 Suppl 1():S40-50. PubMed ID: 19766889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacoeconomics in the new millennium. A pharmaceutical industry perspective.
    Thwaites R; Townsend RJ
    Pharmacoeconomics; 1998 Feb; 13(2):175-80. PubMed ID: 10178645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Barriers to implementing pharmacoeconomics: interview study.
    Alefan Q; Hamdouni E; Alhamad H; Mukattash T; Rascati K
    Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):93-104. PubMed ID: 32394752
    [No Abstract]   [Full Text] [Related]  

  • 30. [Antibiotic pharmacoeconomics].
    Jahnz-Rózyk K
    Pol Merkur Lekarski; 2008 Nov; 25(149):437-8. PubMed ID: 19177784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A changing paradigm in the study and adoption of emerging health care technologies: coverage with evidence development.
    Wallner PE; Konski A
    J Am Coll Radiol; 2008 Nov; 5(11):1125-9. PubMed ID: 18954812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacoeconomics in oncology.
    Arbuckle RB; Adamus AT; King KM
    Expert Rev Pharmacoecon Outcomes Res; 2002 Jun; 2(3):251-60. PubMed ID: 19807417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incorporation of future costs in health economic analysis publications: current situation and recommendations for the future.
    Gros B; Soto Álvarez J; Ángel Casado M
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):465-9. PubMed ID: 25737028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The future of pharmacoeconomics: a commentary.
    Langley PC
    Clin Ther; 1997; 19(4):762-9; discussion 760-1. PubMed ID: 9377619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacoeconomics: state of the art in 1997.
    Schulman KA; Linas BP
    Annu Rev Public Health; 1997; 18():529-48. PubMed ID: 9143730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The future of best investing in vaccines: the Health Technology Assessment approach.
    La Torre G; de Waure C; Chiaradia G; Mannocci A; Specchia ML; Nicolotti N; Ricciardi W
    Vaccine; 2008 Mar; 26(13):1609-10. PubMed ID: 18289744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Approaches for economic evaluations of health care technologies.
    Tarride JE; Blackhouse G; Bischof M; McCarron EC; Lim M; Ferrusi IL; Xie F; Goeree R
    J Am Coll Radiol; 2009 May; 6(5):307-16. PubMed ID: 19394571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacoeconomics. I].
    Kolár J
    Ceska Slov Farm; 1997 Feb; 46(1):9-13. PubMed ID: 9221090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transferability indices for health economic evaluations: methods and applications.
    Antonanzas F; Rodríguez-Ibeas R; Juárez C; Hutter F; Lorente R; Pinillos M
    Health Econ; 2009 Jun; 18(6):629-43. PubMed ID: 18677724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Japanese healthcare system: lessons to be learned.
    Ikegami N
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):201-4. PubMed ID: 19527091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.